{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:53:33Z","timestamp":1793332413963,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Data on the long-term safety and effectiveness of drug-coated balloons (DCBs) for the treatment of long femoropopliteal atherosclerotic\u00a0lesions in the real-world setting are rare. This study reports 3\u00a0year and 5\u00a0year outcomes of the pre-specified 150\u00a0mm balloon sub-cohort of the IN.PACT Global Study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The IN.PACT Global Study was a prospective, multicentre, international, single-arm study evaluating the performance of the IN.PACT Admiral DCB in real-world patients with femoropopliteal atherosclerotic disease. This pre-specified 150\u00a0mm DCB cohort analysis comprised 107 participants (111 lesions) with all target lesions treated with at least one 150\u00a0mm DCB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean lesion length was 20.3\u2009\u00b1\u20099.2\u00a0cm; 18.0% had in-stent restenosis, 58.6% were totally occluded, and 17.1% were severely calcified. Through 60\u00a0months, the Kaplan\u2013Meier estimate of freedom from clinically driven target lesion revascularization (CD-TLR) was 72.7% [95% confidence interval (CI):62.4%\u201380.5%]. The safety composite endpoint (freedom from device\/procedure-related death through 30\u00a0days; freedom from target limb major amputation and clinically driven target vessel revascularization through 5\u00a0years) was 70.5%. The cumulative incidence of major amputation was 1.0% and all-cause mortality was 18.4% through 60 months. Freedom from CD-TLR rates in the provisional stented and non-stented subgroups through 36\u00a0months were 64.0% [95% CI: 46.1%\u201377.3%] and 81.9% [95% CI: 69.7%\u201389.6%] (log-rank <jats:italic>p<\/jats:italic>\u2009=\u20090.074), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results demonstrate sustained long-term safety of the 150\u00a0mm IN.PACT Admiral DCB for long femoropopliteal atherosclerotic\u00a0lesions in real-world patients. In particular, the results show that DCB angioplasty is an effective revascularization modality in long complex lesions. <jats:italic>ClinicalTrials.gov<\/jats:italic>\u00a0identifier:\u00a0NCT01609296.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Level of Evidence.<\/jats:title>\n                <jats:p>Level 3, Cohort Study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00270-022-03214-y","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T21:02:37Z","timestamp":1658437357000},"page":"1276-1287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Outcomes of the 150\u00a0mm Drug-Coated Balloon Cohort from the IN.PACT Global Study"],"prefix":"10.1007","volume":"45","author":[{"given":"Marianne","family":"Brodmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Lansink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Guetl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Micari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Menk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"9","key":"3214_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763\u2013816.","journal-title":"Eur Heart J"},{"issue":"21","key":"3214_CR2","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.jacc.2015.09.063","volume":"66","author":"JR Laird","year":"2015","unstructured":"Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of in: PACT SFA. J Am Coll Cardiol. 2015;66(21):2329\u201338.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3214_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","volume":"131","author":"G Tepe","year":"2015","unstructured":"Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the in: PACT SFA randomized trial. Circulation. 2015;131(5):495\u2013502.","journal-title":"Circulation"},{"issue":"1","key":"3214_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/1526602817745565","volume":"25","author":"O Iida","year":"2018","unstructured":"Iida O, Soga Y, Urasawa K, et al. Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: 1 year results of the MDT-2113 SFA Japan randomized trial. J Endovasc Ther. 2018;25(1):109\u201317.","journal-title":"J Endovasc Ther"},{"issue":"1","key":"3214_CR5","doi-asserted-by":"publisher","first-page":"e005891","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","volume":"11","author":"PA Schneider","year":"2018","unstructured":"Schneider PA, Laird JR, Tepe G, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the in: PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11(1):e005891.","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"3214_CR6","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/CIRCULATIONAHA.117.028893","volume":"136","author":"P Krishnan","year":"2017","unstructured":"Krishnan P, Faries P, Niazi K, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136(12):1102\u201313.","journal-title":"Circulation"},{"issue":"2","key":"3214_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1406235","volume":"373","author":"K Rosenfield","year":"2015","unstructured":"Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145\u201353.","journal-title":"N Engl J Med"},{"issue":"10","key":"3214_CR8","doi-asserted-by":"publisher","first-page":"e005654","DOI":"10.1161\/CIRCINTERVENTIONS.117.005654","volume":"11","author":"D Scheinert","year":"2018","unstructured":"Scheinert D, Micari A, Brodmann M, et al. Drug-coated balloon treatment for femoropopliteal artery disease. Circ Cardiovasc Interv. 2018;11(10):e005654.","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"3214_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jcin.2017.01.028","volume":"10","author":"A Micari","year":"2017","unstructured":"Micari A, Nerla R, Vadala G, et al. 2-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-long study. JACC Cardiovasc Interv. 2017;10(7):728\u201334.","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"3214_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00270-020-02663-7","volume":"44","author":"G Tepe","year":"2021","unstructured":"Tepe G, Zeller T, Moscovic M, et al. Paclitaxel-coated balloon angioplasty for the treatment of infrainguinal arteries: 24-month outcomes in the full cohort of BIOLUX P-III global registry. Cardiovasc Intervent Radiol. 2021;44(2):207\u201317.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"3214_CR11","doi-asserted-by":"publisher","first-page":"e007730","DOI":"10.1161\/CIRCINTERVENTIONS.118.007730","volume":"12","author":"T Zeller","year":"2019","unstructured":"Zeller T, Brodmann M, Micari A, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain. Circ Cardiovasc Interv. 2019;12(1):e007730.","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"3214_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jcin.2018.02.019","volume":"11","author":"A Micari","year":"2018","unstructured":"Micari A, Brodmann M, Keirse K, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-Year results from the IN: PACT global study. JACC Cardiovasc Interv. 2018;11(10):945\u201353.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"3214_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1177\/1526602820931477","volume":"27","author":"G Torsello","year":"2020","unstructured":"Torsello G, Stavroulakis K, Brodmann M, et al. Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort. J Endovasc Ther. 2020;27(5):693\u2013705.","journal-title":"J Endovasc Ther"},{"issue":"8","key":"3214_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jama.2017.9991","volume":"318","author":"JP Jarow","year":"2017","unstructured":"Jarow JP, LaVange L, Woodcock J. Multidimensional evidence generation and FDA regulatory decision making: defining and using \u201creal-world\u201d data. JAMA. 2017;318(8):703\u20134.","journal-title":"JAMA"},{"issue":"8","key":"3214_CR15","first-page":"355","volume":"26","author":"R Dattilo","year":"2014","unstructured":"Dattilo R, Himmelstein SI, Cuff RF. The compliance 360 degrees Trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol. 2014;26(8):355\u201360.","journal-title":"J Invasive Cardiol"},{"issue":"2 Suppl","key":"3214_CR16","first-page":"I70","volume":"83","author":"P Capek","year":"1991","unstructured":"Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty factors influencing long-term success. Circulation. 1991;83(2 Suppl):I70-80.","journal-title":"Circulation"},{"issue":"18","key":"3214_CR17","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa051303","volume":"354","author":"M Schillinger","year":"2006","unstructured":"Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879\u201388.","journal-title":"N Engl J Med"},{"issue":"2","key":"3214_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00270-012-0492-z","volume":"36","author":"N Chalmers","year":"2013","unstructured":"Chalmers N, Walker PT, Belli AM, et al. Randomized trial of the smart stent versus balloon angioplasty in long superficial femoral artery lesions: the super study. Cardiovasc Intervent Radiol. 2013;36(2):353\u201361.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"3214_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCINTERVENTIONS.109.903468","volume":"3","author":"JR Laird","year":"2010","unstructured":"Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the resilient randomized trial. Circ Cardiovasc Interv. 2010;3(3):267\u201376.","journal-title":"Circ Cardiovasc Interv"},{"issue":"24","key":"3214_CR20","doi-asserted-by":"publisher","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","volume":"7","author":"K Katsanos","year":"2018","unstructured":"Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"3214_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/jamacardio.2019.0325","volume":"4","author":"EA Secemsky","year":"2019","unstructured":"Secemsky EA, Kundi H, Weinberg I, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4(4):332\u201340.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"3214_CR22","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.jvs.2019.04.106","volume":"69","author":"DJ Bertges","year":"2019","unstructured":"Bertges DJ, Sedrakyan A, Schermerhorn ML, et al. RS01 mortality after paclitaxel coated balloon angioplasty and stenting of superficial femoral and popliteal artery. J Vasc Surg. 2019;69(6):e98\u20139.","journal-title":"J Vasc Surg"},{"issue":"1","key":"3214_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00270-019-02329-z","volume":"43","author":"KP Donas","year":"2020","unstructured":"Donas KP, Sohr A, Pitoulias GA, Alfonso F, Torsello G. Long-term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon versus plain balloon angioplasty: a real-world study. Cardiovasc Intervent Radiol. 2020;43(1):2\u20137.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"38","key":"3214_CR24","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1093\/eurheartj\/ehz698","volume":"41","author":"E Freisinger","year":"2020","unstructured":"Freisinger E, Koeppe J, Gerss J, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2020;41(38):3732\u20139.","journal-title":"Eur Heart J"},{"key":"3214_CR25","doi-asserted-by":"crossref","unstructured":"Kumins NH, King AH, Ambani RN, et al. (2020) Paclitaxel-coated peripheral artery devices are not associated with increased mortality. J Vasc Surg","DOI":"10.1016\/j.jvs.2019.10.100"},{"key":"3214_CR26","doi-asserted-by":"crossref","unstructured":"Behrendt CA, Sedrakyan A, Peters F, et al. (2020) Long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg","DOI":"10.1016\/j.jvs.2020.03.005"},{"issue":"2","key":"3214_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1526602820904783","volume":"27","author":"K Dinh","year":"2020","unstructured":"Dinh K, Gomes ML, Thomas SD, et al. Mortality after paclitaxel-coated device use in patients with chronic limb-threatening ischemia: a systematic review and meta-analysis of randomized controlled trials. J Endovasc Ther. 2020;27(2):175\u201385.","journal-title":"J Endovasc Ther"},{"issue":"26","key":"3214_CR28","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","volume":"383","author":"J Nordanstig","year":"2020","unstructured":"Nordanstig J, James S, Andersson M, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med. 2020;383(26):2538\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"3214_CR29","doi-asserted-by":"publisher","first-page":"e018149","DOI":"10.1161\/JAHA.120.018149","volume":"10","author":"JA Gutierrez","year":"2021","unstructured":"Gutierrez JA, Rao SV, Jones WS, et al. Survival and causes of death among veterans with lower extremity revascularization with paclitaxel-coated devices: insights from the veterans health administration. J Am Heart Assoc. 2021;10(4):e018149.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"3214_CR30","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/ccd.30074","volume":"99","author":"W Ullah","year":"2022","unstructured":"Ullah W, Zghouzi M, Sattar Z, et al. Safety and efficacy of drug-coated balloon for peripheral artery revascularization-a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2022;99(4):1319\u201326.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"8","key":"3214_CR31","first-page":"1071","volume":"181","author":"EA Secemsky","year":"2022","unstructured":"Secemsky EA, Song Y, Schermerhorn M, Yeh RW. Update from the longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among medicare beneficiaries: the SAFE-PAD study. Circ Cardiovasc Interv. 2022;181(8):1071\u201380.","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"3214_CR32","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00270-017-1771-5","volume":"40","author":"S Muller-Hulsbeck","year":"2017","unstructured":"Muller-Hulsbeck S, Keirse K, Zeller T, Schroe H, Diaz-Cartelle J. Long-term results from the MAJESTIC Trial of the eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up. Cardiovasc Intervent Radiol. 2017;40(12):1832\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3214_CR33","doi-asserted-by":"crossref","unstructured":"Dake MD, Ansel GM, Jaff MR, et al. (2016) Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. circulation, 133(15): 1472\u20131483; discussion 1483","DOI":"10.1161\/CIRCULATIONAHA.115.016900"},{"key":"3214_CR34","doi-asserted-by":"crossref","unstructured":"Laird JR, Katzen BT, Scheinert D, et al. (2012) Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther, 19(1): 1\u20139","DOI":"10.1583\/11-3627.1"},{"issue":"1","key":"3214_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ccd.25895","volume":"86","author":"KJ Rocha-Singh","year":"2015","unstructured":"Rocha-Singh KJ, Bosiers M, Schultz G, et al. A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the durability II trial. Catheter Cardiovasc Interv. 2015;86(1):164\u201370.","journal-title":"Catheter Cardiovasc Interv"},{"key":"3214_CR36","doi-asserted-by":"crossref","unstructured":"Lyden SP, Faries PL, Niazi KAK, et al. (2022) No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes. J Endovasc Ther:15266028211068769","DOI":"10.1177\/15266028211068769"},{"key":"3214_CR37","doi-asserted-by":"crossref","unstructured":"Tepe G, Schnorr B, Albrecht T, et al. (2015) Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv, 8(1 Pt A):102\u2013108","DOI":"10.1016\/j.jcin.2014.07.023"},{"issue":"6","key":"3214_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.118.007702","volume":"12","author":"JA Laird","year":"2019","unstructured":"Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. 2019;12(6): e007702.","journal-title":"Circ Cardiovasc Interv"},{"key":"3214_CR39","doi-asserted-by":"publisher","unstructured":"Zeller T, Brodmann M, Ansel GM, et al. (2022) Paclitaxel-coated balloons for femoropopliteal peripheral arterial disease: final five-year results of the IN.PACT Global Study. EuroIntervention. https:\/\/doi.org\/10.4244\/EIJ-D-21-01098.","DOI":"10.4244\/EIJ-D-21-01098"},{"issue":"16","key":"3214_CR40","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.jcin.2017.04.041","volume":"10","author":"M Thieme","year":"2017","unstructured":"Thieme M, Von Bilderling P, Paetzel C, et al. The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon. JACC Cardiovasc Interv. 2017;10(16):1682\u201390.","journal-title":"JACC Cardiovasc Interv"},{"key":"3214_CR41","doi-asserted-by":"crossref","unstructured":"Scheinert D (2018) Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study Long Lesion Imaging Cohort. Circ Cardiovasc Interv, 11:e005654","DOI":"10.1161\/CIRCINTERVENTIONS.117.005654"},{"key":"3214_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2261-5-14","volume":"5","author":"J Caro","year":"2005","unstructured":"Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord. 2005;5:14.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"3214_CR43","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jvs.2013.11.063","volume":"59","author":"T Mueller","year":"2014","unstructured":"Mueller T, Hinterreiter F, Luft C, Poelz W, Haltmayer M, Dieplinger B. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J Vasc Surg. 2014;59(5):1291\u20139.","journal-title":"J Vasc Surg"},{"issue":"3","key":"3214_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1583\/13-4618R.1","volume":"21","author":"T Miura","year":"2014","unstructured":"Miura T, Soga Y, Miyashita Y, et al. Five-year prognosis after endovascular therapy in claudicant patients with iliofemoral artery disease. J Endovasc Ther. 2014;21(3):381\u20138.","journal-title":"J Endovasc Ther"},{"key":"3214_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.avsg.2020.08.003","volume":"70","author":"NH Kumins","year":"2021","unstructured":"Kumins NH, King AH, Ambani RN, et al. Paclitaxel-coated peripheral arterial devices are associated with reduced mortality in younger patients. Ann Vasc Surg. 2021;70:70\u20138.","journal-title":"Ann Vasc Surg"},{"issue":"20","key":"3214_CR46","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.jacc.2019.01.013","volume":"73","author":"PA Schneider","year":"2019","unstructured":"Schneider PA, Laird JR, Doros G, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73(20):2550\u201363.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3214_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/ccd.29152","volume":"96","author":"PA Schneider","year":"2020","unstructured":"Schneider PA, Brodmann M, Mauri L, et al. Paclitaxel exposure: long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. Catheter Cardiovasc Interv. 2020;96(5):1087\u201399.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"3214_CR48","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1161\/01.CIR.67.4.723","volume":"67","author":"G Dorros","year":"1983","unstructured":"Dorros G, Cowley MJ, Simpson J, et al. Percutaneous transluminal coronary angioplasty: report of complications from the national heart, lung, and blood institute PTCA registry. Circulation. 1983;67(4):723\u201330.","journal-title":"Circulation"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-022-03214-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T22:05:36Z","timestamp":1662674736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-022-03214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3214"],"URL":"https:\/\/doi.org\/10.1007\/s00270-022-03214-y","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The citations for Fig. 3 and Fig. 4 on page 8  have been switched to their correct positions.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marianne Brodmann has received speaking honoraria from Bard Peripheral Vascular, Biotronik, Medtronic, Philips\u2010Spectranetics, Shockwave, Bayer Healthcare, and VIVA Physicians; and is a consultant for Bard Peripheral Vascular, Bayer, Biotronik, Intact Vascular, Medtronic, Philips\u2010Spectranetics, Sanofi, and Shockwave.Wouter Lansink has received speaking honoraria from Abbott, Bard Peripheral, Biotronik, Boston Scientific, Medtronic, and Philips-Spectranetics and has received clinical trial funds from Bard Peripheral, Biotronik, Boston Scientific, I-vascular, Medtronic, and Philips-Spectranetics.Katharina Guetl has nothing to disclose.Antonio Micari has served as a member of the advisory board for Boston Scientific and Medtronic and has served as a consultant for Bard, Boston Scientific, and Terumo.Jeremiah Menk is a full-time employee of Medtronic Inc., Minneapolis, MN.Thomas Zeller has received honoraria from Abbott Vascular, Biotronik, Boston Scientific, Cook Medical, Gore and Associates, Medtronic, Philips\u2010Spectranetics, TriReme, Shockwave, and Veryan; has served as a consultant for Bayer, B. Braun, Boston Scientific, Cook Medical, Gore and Associates, Intact Vascular, Medtronic, Shockwave, Philips-Spectranetics, Veryan, and Vesper Medical; has received research, clinical trial, or drug study funds from 480 biomedical, Bard Peripheral Vascular, B. Braun, Biotronik, Cook Medical, Gore and Associates, Intact Vascular, Med Alliance, Medtronic, Philips-Spectranetics, Terumo, TriReme, and Shockwave; and owns common stock in QT Medical and Veryan.<b>Ethical Approval.<\/b>All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.The Institutional Review Board or Ethics Committee at each study site approved the study protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"For this type of study, consent for publication is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}